Thema: US36254L4077
GTBP, US36254L4077
finance-6097979_1920.jpg - Foto: THN
GT Biopharma stock heads toward SITC presentation on November 6
GT Biopharma stock is set for a clinical-stage immuno-oncology presentation. The company will discuss a KRAS-linked NK-cell therapy approach.
ad-hoc-news.de, vor 57 Minuten
GTBP, US36254L4077
GT Biopharma proposes 250 million shares and dilution risk ...
GT Biopharma seeks 250 million shares on November 11, 2026. For GT Biopharma stock, 2,061,052 shares were outstanding on September 30, 2026.
ad-hoc-news.de, 16.10.26 01:22 Uhr
GTBP, US36254L4077
GT Biopharma registers 13.5M shares: what it means for GT ...
The October 9 filing lists 2,061,052 shares outstanding. Its dilution risk shapes GT Biopharma stock through 2026 and beyond.
ad-hoc-news.de, 14.10.26 04:33 Uhr
GTBP, US36254L4077
GT Biopharma regains Nasdaq compliance: what it means for ...
Nasdaq restored compliance September 22, 2026 after 10 sessions above USD 1.00. GT Biopharma stock had USD 7.7 million market value October 2, 2026.
ad-hoc-news.de, 05.10.26 06:03 Uhr
GTBP, US36254L4077
GT Biopharma sells USD 7.75 million: what it means for GT ...
